AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02017795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic asthma action plan (eAAP)
Description: An electronic asthma action plan (eAAP) will be provided to intervention group
Study NCT02017795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written asthma action plan (WAAP)
Description: A written asthma action plan will be given to control group arm
Study NCT03089268 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: A colonoscopy will be performed to all individuals.
Study NCT03089268 — intervention group
Intervention type: PROCEDURE
Intervention: Polypectomy or biopsy
Description: All lesions will be removed or biopsied during the procedure
Study NCT03089268 — intervention group
Intervention type: GENETIC
Intervention: Molecular analysis
Description: Molecular analysis will be performed in all colorectal cancers and in those polyps diagnosed with serrated lesion
Study NCT02062164 — intervention group
Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: The intervention takes place in the clinical care setting. The decision for surgery is made by a multidisciplinary team, according to the international guidelines and the recommendations of the German working group on obesity (AGA, www.a.g.a.de). The choice of procedure is made on an individual basis taking into consideration patient inherent factors as well as the recommendations of the operating center. Operations are conducted at certified bariatric centers according to the policies of the German working group on bariatric surgery (CAADIP), and in the context of a structured preparation and follow-up program. The program is offered by a multidisciplinary team (pediatrician, endocrinologist, surgeon, dietician, psychologist/psychiatrist, social worker) and comprises preparation for and education about the surgery and expected lifestyle changes, as well as a structured, multidisciplinary follow-up plan. Subjects sign a contract agreeing to adhere to the recommended follow-up schedule.
Study NCT02062164 — intervention group
Intervention type: OTHER
Intervention: conservative care
Description: Subjects will be seen by a trained study physician every 6 months. Stuctured health assessments will be conducted, and individual treatment recommendations will be made based on the patients motivation and ability(e.g. inpatient obesity rehab, exercise, dietary or behavioral intervention etc.)
Study NCT04546139 — intervention group
Intervention type: OTHER
Intervention: footwork
Description: six-point footwork
Study NCT03024203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation - Executive Training
Description: Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as memory, and problem solving ability.
Study NCT03024203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation - Perceptual Training
Description: Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as attention, and processing speed.
Study NCT02932774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
Study NCT02932774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
Study NCT02932774 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syrup once daily before 10:00 AM for 2 weeks
Study NCT03493763 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 5hmC profile in plasma cell-free DNA after liver resection
Description: Peripheral blood is drawn every 3 months after liver resection for 5hmC test (Time frame: 2 years or until tumor recurrence).
Study NCT06159933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Late pronation
Description: According to our local protocol, until December 2021, all patients developing PGD >1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
Study NCT02815735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: contact lens
Study NCT04061226 — intervention group
Intervention type: DEVICE
Intervention: Overnight polysomnography
Description: Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined
Study NCT01357330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245408 (XL147)
Description: Pharmaceutical form:capsule and tablet Route of administration: oral
Study NCT01357330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC1936369B
Description: Pharmaceutical form:capsule Route of administration: oral
Study NCT02456701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379
Description: IV every 2 weeks
Study NCT02815735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: contact lens
Study NCT03398434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAA868
Description: 3 MAA868 doses, single administration, subcutaneous,
Study NCT02456701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg po bid
Study NCT00203060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline Mesylate
Description: tablet, 1 or 2 mg, daily, 58 weeks
Study NCT00203060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet, once daily, 58 weeks
Study NCT00709059 — intervention group
Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks
Study NCT00709059 — intervention group
Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered based on body weight 800-1200 mg/day (\<65 kg: 800 mg; 65 - 85 kg: 1000 mg; >85 kg: 1200 mg) orally for 48 weeks
Study NCT02294136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prep-C
Description: PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.
Study NCT02294136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Description: Attention Control
Study NCT03960177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Given IV
Study NCT03960177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04745962 — intervention group
Intervention type: DEVICE
Intervention: Slimscope
Description: Slimscope thin EBUS endoscope is inserted and used to visualize lung nodules.
Study NCT03398434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Apixaban 5 mg b.i.d
Study NCT00762723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trinica Anterior Lumbar Plate System
Description: Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
Study NCT00712010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein native
Description: versus the six other arms
Study NCT00712010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein
Description: versus the six other arms
Study NCT00712010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total milk protein native
Description: versus the six other arms
Study NCT00712010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk protein
Description: versus the six other arms
Study NCT00198081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-2 Inhibitor 6-8 weeks prior to surgery
Description: 400 mg BID 6-8 weeks prior to surgery
Study NCT00198081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
Description: 400 mg BID for 6 months prior to follow-up EUS or ERCP
Study NCT00376571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment
Study NCT00525967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone plus Acetaminophen or Placebo
Description: Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
Study NCT00525967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone plus Acetaminophen or Placebo
Description: Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
Study NCT03655093 — intervention group
Intervention type: OTHER
Intervention: Validation of AMSQ questionnaire
Description: Participation in the study will be proposed to any patient meeting the inclusion criteria and consulting a neurologist from the SEP reference center of the University Hospital of Rennes.~The neurologist will explain the purpose of the study to the patient, give him the information form.~Without opposition from the patient, the neurologist will give him the self-questionnaire. The patient will fill it during the consultation. In case of disability to the upper limbs making it impossible to fill the questionnaire by the patient, it will be filled by the neurologist or the patient's companion, according to the answers given by the patient.~While the patient completes the questionnaire, a record of clinical information will be filled in by the neurologist.~No additional act will be performed except the questionnaire, which result will not change the patient's management.
Study NCT02157649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR Tablet under Fasted conditions
Description: Administration of IR Tablets combination of Codeine Phosphate/Guaifenesin 20mg/400mg every 4 hours for 12 hours total.
Study NCT02157649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER Tablet under Fed Conditions
Description: Administration of two ER Tablet combination of Codeine Phosphate/Guaifenesin 30mg/600mg
Study NCT02157649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER Tablet under Fasted Conditions
Description: Administration of two Codeine Phosphate/Guaifenesin 30mg/600mg ER Tablets under fasted conditions.
Study NCT02056366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: α-lipoic acid
Description: α-lipoic acid 600mg PO medication,Per day, For 6weeks α-lipoic acid 1200mg PO medication,Per day, For 6weeks
Study NCT01640379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Enhanced Community Health Nursing
Description: * Text-messaging (twice daily medication reminders w/ positive adherence messages, positive sexual health messages throughout the 30 day treatment period)~* Enhanced community health nursing visit on day 3-5, includes evidence-based STI/HIV prevention component (Sister to Sister Teen)
Study NCT00533702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B (ramucirumab)
Description: 10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
Study NCT00533702 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMC-1121B (ramucirumab)
Description: 10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
Study NCT00533702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
Study NCT03884517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8003
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
Study NCT03358459 — intervention group
Intervention type: OTHER
Intervention: non
Description: non
Study NCT03651115 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: therapeutic drug monitoring
Description: To monitor the blood concentrations of gentamicin and vancomycin
Study NCT01489215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: presence
Description: constant presence of the parent in the child's room throughout the night during the first week of the intervention. In addition to sleeping near the child's crib, the parents repeat the same routines as in the checking method if the child is actively protesting or crying.
Study NCT01489215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: checking
Description: putting the child into the crib at bedtime and leaving the room with repeated quick visits every 5 minutes if the child is actively protesting or crying, providing brief reassurance, helping the child to resume a sleeping position.
Study NCT04412343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Group Intervention
Description: Participants will receive weekly exercise courses delivered virtually to a group of older adults. This intervention will last for 12 weeks. Participants in addition to participating in exercise will have designated time after each exercise class to socially connect. Participants in this condition will also receive a t-shirt.
Study NCT04412343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Exercise Intervention
Description: Participants will receive weekly exercise courses delivered virtually. These classes will be pre-recorded so the individual can complete sessions at any time that is convenient for them.
Study NCT03774524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 μg of sublingual misoprostol
Study NCT03774524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: 1 gm of tranexamic acid in 100 ml saline iv
Study NCT03774524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to misoprostol
Description: placebo tablets to misoprostol subligual
Study NCT03774524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to misoprostol
Description: placebo tablets to misoprostol subligual
Study NCT03774524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to TA
Description: 110 ml saline iv
Study NCT02218736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-501
Description: Oral dosing of 10 mg CERC-501 daily for 8 weeks
Study NCT02218736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral dosing of 10 mg placebo daily for 8 weeks
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab Injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Doxorubicin Hydrochloride
Description: Doxorubicin Hydrochloride Injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Epirubicin hydrochloride
Description: Epirubicin hydrochloride injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Fluorouracil
Description: Fluorouracil injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Gemcitabine
Description: Gemcitabine injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Cisplatin
Description: Cisplatin injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Recombinant Human Endostatin
Description: Recombinant Human Endostatin Injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Pirarubicin hydrochloride
Description: Pirarubicin hydrochloride injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Pyrrolidine
Description: Pyrrolidine tablets
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Ixabepilone
Description: Ixapilone Injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Tamoxifen citrate
Description: Tamoxifen citrate tablets
Study NCT04359095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/tenofovir
Description: Generic drug distributed by the Colombian Health System for Human Immunodeficiency Virus (HIV) positive patients It is classified as an anti infectious drug and its current indications include HIV infections.
Study NCT04359095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Pill
Description: Generic drug distributed by the Colombian Health System as an insurance treatment for Gout. It has been suggested that colchicine would be useful in SARS Covid 19 becouse its antiinflammatory effects through reduction of cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome
Study NCT04359095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Generic drug distribute by the Colombian Health System. It is used in people with High levels of cholesterol. An action against the main protease (Mpro) of COVID 19 virus has been described, There is evidence suggesting that statins could exert anti Covid 19 action and the infectivity of enveloped viruses
Study NCT04359095 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: Standard treatment n, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient. No viral therapies are included.
Study NCT04538963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic Band affixed with Glass Ionomer Cement
Description: Glass ionomer cement utilized to affix a blank orthodontic band to the tooth; the mechanical retention of the band will also help retain cement in contact with the tooth- the hypothesis is that the fluoride release from the cement will aid in remineralization of tooth structure.
Study NCT04209972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision Ultra-High-Resolution CT scanner
Description: Patients will be divided on one of the two CT scanners. This group will be scanned on the Precision CT scanner.
Study NCT04209972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genesis high-end CT scanner
Description: Patients will be divided on one of the two CT scanners. This group will be scanned on the Aquilion one Genesis.
Study NCT01461200 — intervention group
Intervention type: OTHER
Intervention: Swab of vestibule and middle meatus of nose
Description: Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
Study NCT03329118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824, Simvastatin
Description: two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
Study NCT04299997 — intervention group
Intervention type: OTHER
Intervention: Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.
Description: 1. Ass of targeted suspect lesions~   On each mpMRI,radiologist will contour lesions that were targeted at subsequent biopsy based on reports. Contours will be disclosed to readers who will assess,for each lesion:~  * Likert score(gut feelingie subjective ass of the likelihood that lesion is clinically significant prostate cancer(5-level scale))~  * PI-RADSv2, PI-RADSv2.1 score(by strictly applying the published PI-RADS criteria)~  * EPE score(ie the likelihood of extraprostatic extension;5-level subjective scale without predefined criteria)~  * Max diameter~2. Def of add suspect lesions Readers could define suspectadditional targets(AT);for each AT,they will provide the same criteria. It is expected that, for these suspect AT,at least one score is≥3~3. Ass of lobes Scores of prostate lobes will be automatically calculated based on 2 previous steps of reading. However,in lobes with no suspect lesion,readers could define whether same criteria are1or2,in peripheral zone and transition zone
Study NCT01047345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
Study NCT01047345 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: V503
Description: V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
Study NCT01047345 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to V503
Description: Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study